Skip to main
BNTX

BioNTech SE (BNTX) Stock Forecast & Price Target

BioNTech SE (BNTX) Analyst Ratings

Based on 13 analyst ratings
Buy
Strong Buy 46%
Buy 23%
Hold 31%
Sell 0%
Strong Sell 0%

Bulls say

BioNTech is projected to have a firm value of $33B, with an 8% discount rate and 2.0% terminal growth rate. Risks for the company include but are not limited to negative data for multiple of its programs, slower market uptake, potential delays in program advancement, partnership and M&A risks, regulatory risks, commercial risks, and possible long-term dilution risk.

Bears say

BioNTech is currently facing risks with its ROSETTA Lung-01 and Lung-02 trials as the recent Chinese data on pumitamig showed similar results to the global Phase 2 trial with an 82% confirmed ORR in 1L ES-SCLC and a 46.7% cORR in 1L NSCLC regardless of PD-L1 expression. Although these results are promising, they also raise concerns about the potential success of BioNTech's Phase 3 trials, which could affect the company's future revenue and profitability. Additionally, the company's heavy reliance on its Pfizer-partnered covid vaccine, Comirnaty, leaves it vulnerable to any potential setbacks or competition in the market, making it a risky investment option.

BioNTech SE (BNTX) has been analyzed by 13 analysts, with a consensus rating of Buy. 46% of analysts recommend a Strong Buy, 23% recommend Buy, 31% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of BioNTech SE and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About BioNTech SE (BNTX) Forecast

Analysts have given BioNTech SE (BNTX) a Buy based on their latest research and market trends.

According to 13 analysts, BioNTech SE (BNTX) has a Buy consensus rating as of Sep 14, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $123.85, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $123.85, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

BioNTech SE (BNTX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.